Abstract: Crystalline calcium pseudomonate or a hydrate thereof, in particular the dihydrate.Processes for the preparation of these salts and their use in human and veterinary medicine and as a growth promoter in animals are described.

Abstract: Organic values are salvaged from scrap polycarbonate by heating in the presence of an acid catalyst and a C.sub.1-4 alkyl phenol such as m- or p-cresol. Among the compounds which can be salvaged are polyalkylated xanthenes, phenol and diaryl carbonate.

Abstract: A process for the production of a mixture of substantially odorless fatty alcohol ethersulfate salts corresponding to formula (I):R.sup.1 --(OCH.sub.2 CH.sub.2).sub.n --O--SO.sub.3 X (I)in whichR.sup.1 is an alkyl radical containing from 6 to 18 carbon atoms,n is a number of from 1 to 10, andX is an alkali metal, alkaline earth metal, ammonium, or alkanolammonium ion,comprising the steps ofA) ethoxylating a fatty alcohol mixture in which the content of components having a boiling point below 235.degree. C. is not more than 0.5% by weight, based on the weight of the fatty alcohol mixture;B) sulfating the fatty alcohol ethoxylate mixture from step A; andC) neutralizing the sulfated fatty alcohol ethoxylate mixture from step B to form said mixture of substantially odorless fatty alcohol ethersulfate salts.

Abstract: Hemiacetals of glyoxal monoacetals are useful as intermediates to prepare 2-substituted but-2-en-1,4-dial-4-acetals of the general formula I; ##STR1##

Abstract: Sulfonated diphosphines of the formula ##STR1## in which Ar is m--C.sub.6 H.sub.4 --SO.sub.3 M, M is hydrogen, ammonium, a monovalent metal, or the chemical equivalent of a polyvalent metal; Ph is phenyl; the m's are individually 1 or 2, and the n's are individually 0, 1, or 2. A method of their preparation and the hydroformylation of olefins and olefinically unsaturated compounds using these compounds as a constituent of water-soluble catalyst systems are also disclosed.

Abstract: A process for the preparation of 2-(substituted)-4-sulfobenzoic acid by oxidation of 2-(substituted)-4-toluenesulfonic acid.

Abstract: Described are novel reversible photochromic diaryl-3H-naphtho[2,1-b]pyran compounds having a substituted or unsubstituted, five or six member heterocyclic ring fused to the g, i, or l side of the naphthopyran. The heterocyclic ring contains an oxygen or nitrogen atom and is attached to the number 5, 6, 7, 8, 9, or 10 carbon atom of the naphtho portion of the naphthopyran. Also described are organic host materials containing such compounds. Articles such as ophthalmic lenses or other plastic transparencies that incorporate the novel naphthopyran compounds or combinations thereof with complementary photochromic compounds, e.g., spiro(indoline)oxazine-type compounds, are also described.

Abstract: Novel compounds are disclosed having the formula ##STR1## and R.sub.1, R.sub.2, R.sub.3, R.sub.4, R.sub.5, R.sub.6 and R.sub.7 are as defined herein. These compounds are useful, for example, as cardiovascular agents and especially as anti-ischemic agents.

Abstract: ConstitutionTricyclic heterocyclyl compounds having a general formula (I): ##STR1## wherein: R.sup.1 and R.sup.2 each represents H, a lower alkyl or lower alkoxy group, a halogen atom or halogeno-lower alkyl; R.sup.3 represents H or a lower alkyl group; R.sup.4 represents a substituted phenyl or naphthyl group; R.sub.5 represents H or a lower alkyl group; A represents a lower alkylene group; B represents an --O-- or --S-- group; and n is 0-1.EffectThe compounds have an excellent activity in the inhibition of acyl-CoA: cholesterol acyltransferase (ACAT) and are useful for the treatment and prophylaxis of atherosclerosis.

Abstract: There are described novel biocatalytic and chemical processes for the synthesis of various oxygenated compounds. Particularly, there are described processes for the synthesis of a useful synthon 12 made by reacting a protected diol (acetonide) with permaganate under appropriate conditions. Such synthon is useful of the synthesis of various pharmaceutically important compounds such as D-chiro-inositol and D-chiro-3-inosose. Also, there are disclosed novel compounds, including specifically the synthon 12 and compounds derived therefrom.

Abstract: According to the invention, a new process for the preparation of fluorine-substituted aminobenzodioxoles and -benzodioxanes of the formula (I) ##STR1## in which n represents an integer 1 or 2, has been found, in which fluorine-substituted nitro-halogeno-benzodioxoles and -benzodioxanes, which are likewise new, are hydrogenated. The novel intermediates are obtained from fluorine-substituted benzodioxoles and benzodioxanes by halogenation and subsequent nitration. The amino compounds are important starting materials for highly active biocides.

Abstract: 1,2,4-trioxane derivatives of formula: ##STR1## (wherein each of the subscripts m and n is equal to 0 or 1;the symbol Z represents an epoxide oxygen atom at the 5,6 or 6,7 positions, or a pair of electrons forming a double bond at the 5,6 or 6,7 positions;each of the symbols Ar.sup.1 and Ar.sup.2, being the same or different represents an aromatic group which optionally substituted;each of the symbols AR.sup.1 and R.sup.2, being the same or different, represents a linear or branched alkyl group, which is optionally substituted, or R.sup.1 and R.sup.

Abstract: A process for preparing the polyhydric phenol compounds represented by the formula (I): ##STR1## (wherein R.sub.1, R.sub.2 and R.sub.3 represent independently hydrogen atom, alkyl group, etc.) which comprises subjecting the compounds represented by the formula (II): ##STR2## (wherein R.sub.1, R.sub.2 and R.sub.3 are as defined above) to a condensation reaction with pyrogallol in the presence of an organic solvent and an acid catalyst.

Abstract: The present invention relates to novel photoactivable rhodamine derivatives for enhancing high quantum-yield production and singlet oxygen generation upon irradiation with light while maintaining desirable differential retention of rhodamine between normal and cancer cells, said derivatives are selected from the group consisting of 4,5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid methyl ester hydrochloride); 4, 5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid ethyl ester hydrochloride); 4, 5-dibromorhodamine 123 (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid octhyl ester hydrochloride); 4,5-dibromorhodamine 110 n-butyl ester (2-(4,5-dibromo-6-amino-3-imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride); Rhodamine B n-butyl ester (2-(6-ethyl amino-3-ethyl imino-3H-xanthen-9-yl)-benzoic acid n-butyl ester hydrochloride); and photoactivable derivatives thereof; whereby photoactivation of the derivatives induces c

Abstract: The present invention relates to 2-deoxy-N-acetylneuraminic acid derivatives and methods for their preparation.

Abstract: Polyalkylated xanthenes are prepared by effecting reaction between an alkylated phenol such as m-cresol and an oxygenated organic material such as acetone in the presence of an acid catalyst such as methanesulfonic acid.

Abstract: Described are novel reversible photochromic naphthopyran compounds, examples of which are compounds substituted at the 3 position of the pyran ring with (i) an aryl substituent and (ii) a phenyl substituent having a 5- or 6-member heterocyclic ring fused at the number 3 and 4 carbon atoms of the phenyl substituent, and at the 6 position of the naphthyl portion of the naphthopyran compound with a nitrogen-containing heterocyclic ring. Also described are organic host materials that contain or that are coated with such compounds. Articles such as ophthalmic lenses or other plastic transparencies that incorporate the novel naphthopyran compounds or combinations thereof with complementary photochromic compounds, e.g., spiro(indoline) type compounds, are also described.

Abstract: The compounds of formulaa. ##STR1## wherein symbol X represents a --CHO group or a group of formula ##STR2## in which symbols R', taken separately, represent each a C.sub.1 to C.sub.4, linear or branched, saturated or unsaturated alkyl radical, or taken together represent a substituted or unsubstituted C.sub.2 to C.sub.4 alkylene radical; symbol R.sup.2 represents a hydrogen atom or a methyl radical; and R.sup.1 and R.sup.3 are different and represent each a hydrogen atom or a methyl radical;or of formulab. ##STR3## wherein the tert-butyl radical is located in position 5 or 6 of the aromatic ring and, either Y represents hydrogen and X and R.sup.2 have the meaning indicated above, or X and R.sup.2 represent each a hydrogen atom and Y represents a --CH.sub.2 CHO group or a group of formula ##STR4## in which R' is defined as in a.; or of formulac. ##STR5## wherein X and R.sup.

Abstract: A process for preparing fluorocarbon fluoroalkanesulfonates comprises (a) forming a mixture comprising at least one fluoroalkanesulfonyl halide, e.g., perfluoromethanesulfonyl fluoride, at least one fluorocarbon-substituted carbinol, e.g., 1,1-dihydroperfluorobutoxyethoxyethanol, and at least one base, e.g., triethyl amine; and (b) allowing the mixture to react in the absence of solvent at a temperature below ambient. The process is volume-efficient and provides high yields of fluorocarbon fluoroalkanesulfonates useful as intermediates in, e.g., drug synthesis.

Abstract: This invention relates to novel hydrazide acyl hydrazinium derivatives of certain 3,4-dihydro-2H-1-benzopyrans of the formula ##STR1## the stereoisomers and mixtures thereof, their inner salts, and the pharmaceutically acceptable salts thereof whereinR is H or C.sub.1-6 alkyl,R.sub.1 is C.sub.1-6 alkyl,R.sub.2 is H or --C(O)R,R.sub.3 and R.sub.4 are independently C.sub.1-6 alkyl;R.sub.5 is C.sub.1-6 alkyl, or ##STR2## with R.sub.8 being H or halogeno, n is zero, 1, 2, or 3 andis a halide, --S(O).sub.3 R.sub.6, or nothing when the inner salt is formedR.sub.6 is H, C.sub.1-6 alkyl, phenyl or 4-methylphenyl,to the intermediates, processes and techniques for their preparation, to their ability to manifest the property of being free radical scavengers, and to their end-use application in the treatment of disease conditions capable of being ameliorated by free radical scavengers.